• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Challenges of the Omicron (B.1.1.529) Variant and Its Lineages: A Global Perspective.奥密克戎(B.1.1.529)变体及其谱系的挑战:全球视角。
Chembiochem. 2022 May 4;23(9):e202200059. doi: 10.1002/cbic.202200059. Epub 2022 Mar 23.
2
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.关于关注的 SARS-CoV-2 奥密克戎变异株及其特殊突变特征的最新信息。
Microbiol Spectr. 2022 Apr 27;10(2):e0273221. doi: 10.1128/spectrum.02732-21. Epub 2022 Mar 30.
3
The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity.奥密克戎变异株引发的 SARS-CoV-2 疫情、免疫逃逸和疫苗效力。
J Med Virol. 2023 Jan;95(1):e28138. doi: 10.1002/jmv.28138. Epub 2022 Sep 21.
4
Identification of SARS CoV-2 Omicron BA.1 and a novel Delta lineage by rapid methods and partial spike protein sequences in Sulaymaniyah Province, Iraq.伊拉克苏莱曼尼亚省通过快速方法和部分刺突蛋白序列鉴定 SARS-CoV-2 奥密克戎 BA.1 和一种新型德尔塔谱系。
Immun Inflamm Dis. 2023 Mar;11(3):e801. doi: 10.1002/iid3.801.
5
In silico evaluation of the impact of Omicron variant of concern sublineage BA.4 and BA.5 on the sensitivity of RT-qPCR assays for SARS-CoV-2 detection using whole genome sequencing.基于全基因组测序的奥密克戎变异株 BA.4 和 BA.5 对 SARS-CoV-2 检测 RT-qPCR 检测方法敏感性影响的计算机评估。
J Med Virol. 2023 Jan;95(1):e28241. doi: 10.1002/jmv.28241. Epub 2022 Nov 8.
6
Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.新型关注变异株 SARS-CoV-2 奥密克戎(B.1.1.529)的特征及其全球视角。
J Med Virol. 2022 Apr;94(4):1738-1744. doi: 10.1002/jmv.27524. Epub 2022 Jan 11.
7
Mutation and codon bias analysis of the spike protein of Omicron, the recent variant of SARS-CoV-2.新冠病毒最新变种奥密克戎刺突蛋白的突变与密码子偏好性分析
Int J Biol Macromol. 2023 Oct 1;250:126080. doi: 10.1016/j.ijbiomac.2023.126080. Epub 2023 Aug 2.
8
Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant.SARS-CoV-2 突变级联导致奥密克戎变体的进化和出现。
Virus Res. 2022 Jul 2;315:198765. doi: 10.1016/j.virusres.2022.198765. Epub 2022 Mar 31.
9
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?奥密克戎:为何最新的 SARS-CoV-2 变体如此令人担忧?
J Virol. 2022 Mar 23;96(6):e0207721. doi: 10.1128/jvi.02077-21.
10
Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus-2 Omicron Variant of Concern.新型严重急性呼吸系统综合征冠状病毒 2 关注变体奥密克戎的传播动态和突变流行率。
J Med Virol. 2022 May;94(5):2160-2166. doi: 10.1002/jmv.27611. Epub 2022 Feb 4.

引用本文的文献

1
Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变种的中和单克隆抗体(nMAbs)的治疗潜力
Curr Pharm Des. 2025;31(10):753-773. doi: 10.2174/0113816128334441241108050528.
2
What can traditional plant therapy do in the face of Covid-19? Examples from traditional Chinese medicine.面对新冠疫情,传统植物疗法能做些什么?来自中医药的例子。
Afr Health Sci. 2023 Jun;23(2):56-66. doi: 10.4314/ahs.v23i2.7.
3
Chemical and spectroscopic characterization of (Artemisinin/Querctin/ Zinc) novel mixed ligand complex with assessment of its potent high antiviral activity against SARS-CoV-2 and antioxidant capacity against toxicity induced by acrylamide in male rats.(青蒿素/槲皮素/锌)新型混合配体配合物的化学和光谱特性及其对 SARS-CoV-2 的高效高抗病毒活性和对丙烯酰胺诱导雄性大鼠毒性的抗氧化能力评估。
PeerJ. 2024 Jan 2;12:e15638. doi: 10.7717/peerj.15638. eCollection 2024.
4
EG.5 (Eris) and BA.2.86 (Pirola) two new subvariants of SARS-CoV-2: a new face of old COVID-19.EG.5(Eris)和 BA.2.86(Pirola):两种新的 SARS-CoV-2 亚变体:旧 COVID-19 的新面貌。
Infection. 2024 Apr;52(2):337-343. doi: 10.1007/s15010-023-02146-0. Epub 2024 Jan 3.
5
Analyzing the emerging patterns of SARS-CoV-2 Omicron subvariants for the development of next-gen vaccine: An observational study.分析严重急性呼吸综合征冠状病毒2型奥密克戎亚变体的新出现模式以开发下一代疫苗:一项观察性研究。
Health Sci Rep. 2023 Oct 18;6(10):e1596. doi: 10.1002/hsr2.1596. eCollection 2023 Oct.
6
A retrospective analysis of factors associated with the length of hospital stay in COVID-19 patients treated with Nirmatrelvir / Ritonavir.对接受奈玛特韦/利托那韦治疗的COVID-19患者住院时间相关因素的回顾性分析。
Front Pharmacol. 2023 Jun 5;14:1146938. doi: 10.3389/fphar.2023.1146938. eCollection 2023.
7
SARS-CoV-2 evolved variants optimize binding to cellular glycocalyx.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进化出的变体优化了与细胞糖萼的结合。
Cell Rep Phys Sci. 2023 Apr 19;4(4):101346. doi: 10.1016/j.xcrp.2023.101346. Epub 2023 Apr 7.
8
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗、疫苗开发技术以及疫情期间疫苗开发的重大努力:吸取的经验教训可能有助于抗击下一次大流行。
Vaccines (Basel). 2023 Mar 17;11(3):682. doi: 10.3390/vaccines11030682.
9
Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau.奥密克戎变异株 BA.5 传染性强但可防可控:澳门的成功经验。
Front Public Health. 2023 Jan 10;10:1029171. doi: 10.3389/fpubh.2022.1029171. eCollection 2022.
10
A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies.关于 SARS-CoV-2 奥密克戎的详细概述:其亚变体、突变和病理生理学、临床特征、免疫状况、免疫逃逸以及治疗方法。
Viruses. 2023 Jan 5;15(1):167. doi: 10.3390/v15010167.

本文引用的文献

1
Higher Viral Stability and Ethanol Resistance of Avian Influenza A(H5N1) Virus on Human Skin.禽流感病毒 H5N1 在人类皮肤上具有更高的病毒稳定性和乙醇抗性。
Emerg Infect Dis. 2022 Mar;28(3):639-649. doi: 10.3201/eid2803.211752.
2
SARS-CoV-2 and its variants of concern including Omicron: A never ending pandemic.SARS-CoV-2 及其关注变种,包括奥密克戎:一场永无止境的大流行。
Chem Biol Drug Des. 2022 May;99(5):769-788. doi: 10.1111/cbdd.14035. Epub 2022 Mar 8.
3
Omicron (B.1.1.529) variant of SARS-CoV-2: Concerns, challenges, and recent updates.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎(B.1.1.529)变体:关注、挑战及近期进展
J Med Virol. 2022 Jun;94(6):2336-2342. doi: 10.1002/jmv.27633. Epub 2022 Feb 12.
4
SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo.严重急性呼吸综合征冠状病毒2型奥密克戎变异株在人支气管和肺组织外植体中的复制
Nature. 2022 Mar;603(7902):715-720. doi: 10.1038/s41586-022-04479-6. Epub 2022 Feb 1.
5
Rapid and sensitive identification of omicron by variant-specific PCR and nanopore sequencing: paradigm for diagnostics of emerging SARS-CoV-2 variants.通过变异特异性 PCR 和纳米孔测序快速灵敏地识别奥密克戎:新兴 SARS-CoV-2 变异体诊断的范例。
Med Microbiol Immunol. 2022 Feb;211(1):71-77. doi: 10.1007/s00430-022-00728-7. Epub 2022 Jan 21.
6
Emergence of Omicron third lineage BA.3 and its importance.奥密克戎第三个谱系BA.3的出现及其重要性。
J Med Virol. 2022 May;94(5):1808-1810. doi: 10.1002/jmv.27601. Epub 2022 Jan 23.
7
Plasma Neutralization of the SARS-CoV-2 Omicron Variant.新冠病毒奥密克戎变异株的血浆中和作用
N Engl J Med. 2022 Feb 10;386(6):599-601. doi: 10.1056/NEJMc2119641. Epub 2021 Dec 30.
8
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.奥密克戎变异株对抗体介导的中和作用具有高度抗性:对控制 COVID-19 大流行的影响。
Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24.
9
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses.由 SARS-CoV-2 感染或 mRNA 疫苗引发的抗体对 Beta 和奥密克戎假病毒的中和活性降低。
Sci Transl Med. 2022 Mar 2;14(634):eabn7842. doi: 10.1126/scitranslmed.abn7842.
10
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.奥密克戎对抗体中和作用的逃逸显著。
Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23.

奥密克戎(B.1.1.529)变体及其谱系的挑战:全球视角。

Challenges of the Omicron (B.1.1.529) Variant and Its Lineages: A Global Perspective.

机构信息

Department of Chemistry, Government College of Engineering, Keonjhar, 758002, Odisha, India.

Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, 505417, Telangana, India.

出版信息

Chembiochem. 2022 May 4;23(9):e202200059. doi: 10.1002/cbic.202200059. Epub 2022 Mar 23.

DOI:10.1002/cbic.202200059
PMID:35322516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9083815/
Abstract

The SARS-CoV-2 virus has shown increased ability to mutate over the past two years, especially in the regions of the spike protein and receptor binding sites. Omicron (B.1.1.529) is the fifth variant of concern (VOC) after the emergence of the Alpha, Beta, Gamma, and Delta VOCs of SARS-CoV-2. This new variant has now circulated in 128 countries and according to the Global Initiative on Sharing All Influenza Data (GISAID), these 128 countries have shared 650,657 Omicron genome sequences as of 26 January, 2022. In this article, we highlight the real challenges of Omicron and its different lineages.

摘要

过去两年中,SARS-CoV-2 病毒的突变能力明显增强,尤其是在刺突蛋白和受体结合部位。奥密克戎(B.1.1.529)是继 Alpha、Beta、Gamma 和 Delta 变异株之后出现的第五种关切变异株(VOC)。目前该新变异株已在 128 个国家传播,根据全球共享流感数据倡议组织(GISAID)的数据,截至 2022 年 1 月 26 日,这 128 个国家已共享了 650657 份奥密克戎基因组序列。本文重点介绍了奥密克戎及其不同谱系带来的实际挑战。